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ABSTRACT Type I interferons (IFNs) are key players in the antiviral immune re-
sponse. Interferon alpha (IFN-) belongs to this class of IFNs and comprises 12 sub-
types that differ from each other in their binding afﬁnities for a common receptor
and, thus, in their signaling potencies. Recent data suggest that IFN-6 and -14 are
the most potent IFN- subtypes in restricting HIV replication when applied exoge-
nously. However, in the context of antiviral therapy, IFNs are administered at high
doses, which may compensate for differences in potency seen between IFN- sub-
types. In this study, we reexamined whether IFN- subtypes induce different biologi-
cal activities, with a focus on how IFN- treatment dose affects cellular responses to
HIV in primary CD4 T cells, peripheral blood mononuclear cells (PBMCs), and mac-
rophages. We found that the subtypes’ antiviral activities were dose dependent, with
90% inhibition of HIV replication at a high dose of all IFN-s except the weak IFN-
/ receptor (IFNAR) binder, IFN-1. The quality of the responses engendered by
IFN-1, -2, -6, and -14 was highly comparable, with essentially the same set of
genes induced by all four subtypes. Hierarchal cluster analysis revealed that the indi-
vidual donors were stronger determinants for the IFN-stimulated-gene (ISG) re-
sponses than the speciﬁc IFN- subtype used for stimulation. Notably, IFN-2-
derived mutants with substantially reduced IFNAR2 binding still inhibited HIV
replication efﬁciently, whereas mutants with increased IFNAR1 binding potentiated
antiviral activity. Overall, our results support the idea that IFN- subtypes do not in-
duce different biological responses, given that each subtype is exogenously applied
at bioequivalent doses.
IMPORTANCE Elucidating the functional role of the IFN- subtypes is of particular
importance for the development of efﬁcacious therapies using exogenous IFN-.
Speciﬁcally, this will help deﬁne whether IFN therapy should be based on the use of
pathogen-dependent IFN subtypes or, rather, IFN mutants with optimized IFNAR
binding properties.
KEYWORDS antiviral therapy, human immunodeﬁciency virus, interferons,
therapeutic efﬁcacy
Human type I interferons (IFNs) are key players in protection against viral infections,and their antiviral potency has been harnessed for treating chronic hepatitis B
virus (HBV) and hepatitis C virus (HCV) infections, as well as in clinical trials for
HIV-1-infected individuals (1–4). The family of human interferon alpha (IFN-) is a
subset of type I IFNs comprising 12 distinct proteins that display great genetic and
structural homology (75 to 99% amino acid sequence identity) (5). All IFN- subtypes
Citation Schlaepfer E, Fahrny A, Gruenbach M,
Kuster SP, Simon V, Schreiber G, Speck RF. 2019.
Dose-dependent differences in HIV inhibition
by different interferon alpha subtypes while
having overall similar biologic effects. mSphere
4:e00637-18. https://doi.org/10.1128/mSphere
.00637-18.
Editor Akira Ono, University of Michigan
Medical School
Copyright © 2019 Schlaepfer et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Roberto F. Speck,
Roberto.speck@usz.ch.
E.S. and A.F. contributed equally.
Received 19 November 2018
Accepted 18 January 2019
Published 13 February 2019
RESEARCH ARTICLE
Therapeutics and Prevention
crossm
January/February 2019 Volume 4 Issue 1 e00637-18 msphere.asm.org 1
 o
n
 August 9, 2019 at UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://m
sphere.asm
.org/
D
ow
nloaded from
 
bind to the ubiquitously expressed type I IFN-/ receptor (IFNAR), which is composed
of two transmembrane subunits, IFNAR1 and IFNAR2. Although the IFN- subtypes
form structurally highly comparable ligand-receptor complexes (6), they differ from one
another in their afﬁnities for the IFNAR subunits, ranging from 0.5 to 5 M for IFNAR1
and 0.4 to 5 nM for IFNAR2, with the exception of IFN-1, which displays substantially
lower afﬁnities (7). Binding to the IFNAR complex triggers, via the Jak/STAT pathway,
the transcription of hundreds of IFN-stimulated genes (ISGs) (8). Modulation of IFN-
signaling by an array of other factors and signaling cascades (reviewed in reference 9),
as well as cell type-, pathogen-, and microenvironment-speciﬁc determinants, results in
the induction of distinct subsets of cellular effectors that mediate the diverse biological
responses attributed to IFN-, such as the hundreds of ISGs associated with the
establishment of an antiviral state in infected and neighboring cells (10, 11).
The reason for the existence of so many IFN- subtypes, which all signal through the
same receptor, remains a controversial subject. Indeed, distinct IFN- subtype proﬁles
are elicited in both pathogen- and cell type-speciﬁc manners (12–15), yet whether a
distinct proﬁle is necessary for an effective antiviral immune response is still a matter
of debate (14, 16–18). One perception is that the IFN- subtypes exert distinct func-
tional roles; another perception is that not all the IFN- subtypes are essential in a cell,
but the built-in redundancy is beneﬁcial in case of failure of certain subtypes due to
viral evasion strategies (19). As each IFN- subtype is under the control of its own
promoter, the presence of many subtypes allows dynamics in production levels (15, 20).
Notably, all we know about IFN subtypes’ biological signiﬁcance is based on their
exogenous administration in various in vitro or in vivo settings (1, 16, 19, 21–24).
We previously demonstrated that, although all IFN- subtypes trigger an antiviral
state (6), the afﬁnity and stability of the ternary IFN-–receptor complex dictate, to a
large extent, the distinct biological activities (25). Notably, the high-afﬁnity subtypes
human IFN-5, -6, -8, and -14 have been shown to be the most potent in inhibiting
HIV replication in vitro and in humanized mice (16, 17, 26). Moreover, studies assessing
the antiviral potency of murine IFN- transgene therapy in mouse models of infection
with inﬂuenza virus, murine cytomegalovirus, and herpes simplex virus revealed that
IFN- subtypes exerted distinct antiviral potencies in a virus-speciﬁc manner (21–24).
These results suggest that individual IFN- subtypes possess distinct qualitative prop-
erties. Nevertheless, in these studies, IFN subtypes were provided either as transfected
transgenes or at a single dose, thus precluding the identiﬁcation of possible dose-
dependent effects and a distinction between potency and therapeutic effectiveness. In
addition, antiviral potencies were not always consistent across related experimental
investigations (14, 21, 22, 24). On the other hand, others have shown that given
sufﬁciently high type I IFN doses, the induced ISG responses are qualitatively and
quantitatively similar between IFN subtypes (14, 27). In this regard, as the induced ISG
proﬁle ultimately dictates the cellular response to IFN signaling, it is difﬁcult to resolve
how IFN- subtypes could induce functionally divergent activities. Moreover, when
interferons are administered at pharmacologic (i.e., supraphysiological) doses (19), it is
likely that each IFN- subtype could induce its maximum effect, compensating for
differences in potency.
The prevailing ambiguity regarding the IFN- subtypes’ functional role (reviewed in
reference 28) spurred us to reexamine whether these 12 highly similar cytokines, which
all trigger the same JAK/STAT signaling pathway, can genuinely induce differential
activities or whether our understanding of the IFN- subtypes’ intrinsic properties has
been masked by dose-related effects. To this end, we investigated the antiviral prop-
erties of IFN- subtypes in ex vivo HIV-infected primary cells with a focus on assessing
the dose-dependent effects of a selected set of IFN- subtypes. Furthermore, using a
panel of IFN- mutants with different afﬁnities for IFNAR1 and IFNAR2, we deﬁned
dominant signaling domains responsible for anti-HIV activity. Elucidating the functional
role of the IFN- subtypes is of particular importance for the development of efﬁcacious
therapies using exogenous IFN-, in that such ﬁndings will clarify whether IFN therapy
should be based on pathogen-dependent subtype selection or, rather, on the use of an
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IFN- mutant with optimized IFNAR binding properties, or whether the effects ob-
served for any one IFN are only a question of dose.
RESULTS
Dose-dependent differences in signaling potency between IFN-1, -2, and
-6 with saturation of subtype-speciﬁc differences at 1,000 pg/ml. The overarching
aim of this study was to elucidate whether exogenously applied IFN- subtypes
engender qualitatively different biological responses or whether discrepancies between
subtypes are merely a consequence of the applied dose (i.e., quantitative). As the
cellular responses to IFN- signaling are highly plastic due to signal modulation in a cell
type- and context-dependent manner (6, 11), we ﬁrst screened the 12 distinct IFN-
proteins over a range of doses for their ability to trigger the JAK/STAT pathway and
induce reporter gene expression using a reporter cell line transduced with an IFN-
stimulated response element (ISRE)-luciferase construct. Upon treatment with IFN-,
these reporter cells are induced to express luciferase, and thus, the level of gene
expression can be quantiﬁed by measuring the emitted relative light units (RLU) with
a luminometer. In this assay, IFN-6 and IFN-1 stood out as the strongest and weakest
inducers of gene expression, respectively, over a large dose range (1 to 10,000 pg/ml)
(Fig. 1A). All the other IFN- subtypes did not differ signiﬁcantly in their signaling
activities for the doses tested compared to the results for IFN-2. Notably, at higher
concentrations, differences in reporter gene induction in response to the various IFN-
subtypes waned and were no longer visible as of 1,000 pg/ml, except for IFN-1, which
had to be administered at a dose greater than 1,000 pg/ml to achieve gene expression
levels equivalent to those induced by IFN-2. Although IFN-6 displayed a superior
signaling efﬁciency, the convergence of gene expression levels suggests the existence
of a saturating effect in IFN- signaling through the IFNAR complex, i.e., maximal
receptor complex activation.
IFN- subtypes induce similar ISG response proﬁles at 1,000 pg/ml. To investi-
gate whether the different IFN- subtypes at high doses trigger similar cellular re-
sponses irrespective of their ability to block HIV, we determined the ISG response to
IFN- subtypes 1, 2, 6, and 14 at 1,000 pg/ml in primary CD4 T cells (cells from three
separate donors were tested) using the quantitative real-time interferons and receptors
RT2 PCR Proﬁler array from Qiagen. For this analysis, we focused on the subtypes that
showed the greatest differences in signaling potencies compared to that of IFN-2
(Fig. 1A), as well as that of IFN-14, because of the current interest in this subtype for
HIV therapy (16, 17, 26). Note that only the IFN--responsive genes (i.e., ISGs) included
in the PCR array (i.e., a total of 25 genes) were considered in our analyses, but gene
expression results for the full panel of 84 genes included in the PCR array are provided
in Fig. S1 in the supplemental material. We found that the quality of the responses
engendered by the different IFN-s was similar when applied at a high dose, as
essentially the same set of genes was induced by all subtypes (Fig. 1B). Speciﬁcally, all
subtypes were able to induce a majority (72 to 80%) of the genes included in our
analyses by 2-fold (Table 1). Only two genes were uniquely induced by 2-fold by
IFN-6 and -14 (see genes highlighted blue in Table S1), and only one gene was
downregulated by IFN-1 (see gene highlighted yellow in Table S1), whereas it was
marginally upregulated by the other three subtypes (average fold upregulation, 0.78).
If higher thresholds of gene upregulation were considered, differences in the number
of genes induced by each subtype were not signiﬁcant. Quantitatively, the level of gene
upregulation by each IFN- subtype was consistent with the subtypes’ known afﬁnities
to IFNAR2, i.e., IFN-6 and -14 gave the strongest gene expression responses, followed
by IFN-2 and then IFN-1 (Fig. 1C). Only 10/25 genes were induced to different levels
in at least one pair of IFN responses (Table S2), and yet, it is noteworthy that all of these
genes were induced 2-fold. Taken together, these data suggest that IFN-1, -2, -6,
and -14 effectively have identical signaling properties but differ in their signaling
efﬁciencies, which is in line with what we observed in the experiment whose results are
shown in Fig. 1A.
Dose-Dependent Anti-HIV Effects by IFN- Subtypes
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Hierarchal cluster analysis also revealed that the individual donors were stronger
determinants for the ISG responses than the speciﬁc IFN- subtype used for stimulation
(Fig. 1B). Namely, although the ISG responses induced by IFN-6 and -14 always
clustered together for each donor, ultimately, the responses induced by the different
IFN- subtypes in a given donor were more similar to one another than those induced
by the same IFN- subtype in the three different donors.
FIG 1 Signaling activities of IFN- subtypes converge at high treatment doses, which translates into comparable ISG induction proﬁles between subtypes. (A)
Dose-dependent induction of gene expression by all 12 IFN- subtypes in cells carrying an ISRE-luciferase construct. Signiﬁcance testing was done for each
IFN- dose using one-way ANOVAs on fold activity relative to the activity of IFN-2. Symbols for comparisons with IFN-2 are as follows: *, IFN-1; #, IFN-6.
Presentation of data is described in “Statistical analysis” in Materials and Methods for all ﬁgures. (B) Heat map showing genes induced in primary CD4 T cells
from three independent donors stimulated with 1,000 pg/ml of IFN-1, -2, -6, or -14 compared to their induction in unstimulated controls (i.e., fold
upregulation normalized to the expression in the unstimulated control; the values 3 to 115 represent the extremes of down- and upregulation as normalized
to the result for the unstimulated control), and hierarchical clustering of the induced-gene-response proﬁles. For this assay, the interferons and receptors RT2
Proﬁle PCR array (Qiagen) was used, but only results for genes of interest (ISGs) are shown; see Fig. S2 in the supplemental material for results for the full array
of genes included in the PCR array. (C) Detailed view of genes quantitatively differentially induced by IFN-1, -2, -6, or -14. Lines connect responses from
each donor, and the horizontal dashed line represents 2-fold change in gene expression compared to expression in unstimulated controls. These 10 genes
represent the set of genes that showed signiﬁcantly different expression levels between at least one pair of IFN- subtypes in repeated measures (RM) two-way
ANOVAs of the data set shown in panel B (ANOVA results are summarized in Table S2). Note that all 10 genes were induced 2-fold.
TABLE 1 Average numbers of genes induced in CD4 T cells upon treatment with
saturating dose of selected IFN- subtypesa
Level of
upregulation
No. of genes induced at indicated level (avg
across 3 donors) by IFN- subtype:
P valueb1 2 6 14
2-fold 18 18 20 20 0.0417
3-fold 17 18 18 18 0.0625
5-fold 16 16 16 18 0.1667
aThis analysis considers all 25 genes shown in Fig. 1B. The saturating dose used was 1,000 pg/ml.
bSigniﬁcance testing was done using Friedman’s test (i.e., nonparametric RM one-way ANOVA).
Schlaepfer et al.
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Dose-dependent inhibition of HIV by IFN- subtypes. To examine whether the
dose-dependent differential signaling potencies between IFN- subtypes are related to
their antiviral activities, we explored the ability of IFN- subtypes applied at a range of
concentrations to inhibit HIV replication in primary cells. For these experiments, we
chose IFN-1, -2, and -6 as representatives of low-, intermediate-, and high-
signaling-potency IFN- family members, respectively. As the antiviral activity of IFN-s
may depend on the inoculum dose (29), we ﬁrst assessed the anti-HIV activity of IFN-2
in peripheral blood mononuclear cells (PBMCs) challenged with different doses of HIV.
PBMCs from six healthy donors were pretreated with increasing concentrations of
IFN-2 and infected with HIV at multiplicities of infection (MOIs) in the range of 0.001
to 0.1 (Fig. S2). We found similar dose-inhibition curves at the two lower doses of HIV
and a convergence of antiviral potencies for all MOIs when cells were treated with
1,000 pg/ml of IFN-2. Notably, at lower concentrations (i.e., 1 to 100 pg/ml), IFN-2
was more efﬁcient in inhibiting HIV replication in the PBMCs infected with an MOI of 0.1
than in those infected with lower MOIs (average 50% inhibitory concentration [IC50]
was 236.9 pg/ml at an MOI of 0.001, 96.7 pg/ml at an MOI of 0.01, and 14.5 pg/ml at an
MOI of 0.1). Since we got vigorous HIV replication in all cell types/cultures tested at
an MOI of 0.01 (Fig. S3) and we got dose-dependent inhibition of HIV replication with
an MOI of either 0.1 or 0.01 even though they differed (Fig. S2), we used the lower MOI
to economize on viral stocks.
In a ﬁrst pilot experiment, we tested a wide range of IFN- doses (0.001 to
1,000 pg/ml) and observed a clear dose-dependent inhibition of HIV replication in
CD4 T cells (n 6) and PBMCs (n 3) for all IFN- subtypes tested as of a dose of
1 pg/ml (Fig. 2A). IFN-6 and -14 were more potent than IFN-2 in inhibiting HIV, and
IFN-1 had the lowest potency, in line with the literature (16, 17); however, the anti-HIV
activities of the subtypes studied converged at 1,000 pg/ml. Thus, we followed up with
an extensive analysis of the anti-HIV activities of IFN- subtypes 1, 2, and 6 adminis-
tered at concentrations ranging from 1 to 1,000 pg/ml in primary cells from an
additional six healthy donors (Fig. 2B and Fig. S3). We did not include IFN-14, as it
displayed anti-HIV potency highly comparable to that of IFN-6 in the pilot experiment
(by repeated measures [RM] two-way analysis of variance [ANOVA]: for CD4 T cells,
P 0.9819, and for PBMCs, P 0.5184). The results from this second screen corrobo-
rated the data from the pilot experiment, i.e., IFN-6 was clearly the most potent
anti-HIV IFN- subtype, followed by IFN-2 and then IFN-1, in all cell types tested. We
normalized the data by ﬁrst calculating the area under the curve (AUC) of the p24
antigen (Ag) level over time for each condition and then expressing it as a percentage
of that of the mock-treated HIV-infected control (Fig. 2B). We did this normalization
because of the huge variability in the donors’ HIV permissiveness (at day 12, the mean
p24 Ag levels [95% conﬁdence interval], measured in pg/ml, were 49,152 [21,914 to
76,391] for HIV-infected CD4 T cells, 17,686 [3,958 to 31,414] for HIV-infected
monocyte-derived macrophages (MDMs), and 20,282 [1,359 to 39,206] for HIV-infected
PBMCs), which might mask the actual anti-HIV effect when solely looking at p24 values.
In any case, there is exactly the same trend when looking at the p24 Ag raw data
(Fig. S3), a dose-dependent anti-HIV effect with IFN-6 being the most potent IFN
subtype and IFN-1 being the least potent one.
When normalized to the anti-HIV activity of IFN-2, the anti-HIV activities of the
IFN- subtypes examined converged at higher dosages (Fig. 2C), suggesting a satura-
tion of antiviral activity as of 1,000 pg/ml of any IFN-. Of note, the small differences in
anti-HIV activity between subtypes that persisted in CD4 T cells at 1,000 pg/ml
suggest that this IFN dose is not sufﬁcient to saturate the system in this cell type. The
residual HIV replication (Vres) observed is reminiscent of previous work examining the
ability to inhibit founder HIV strains by either IFN-2 or - (30, 31). Moreover, cell
type-speciﬁc differences in the HIV inhibitory activities of the various IFN- subtypes
tested were observed, with CD4 T cells being overall less responsive to IFN-
treatment than PBMCs and MDMs (Fig. 2D). Furthermore, overall, we found that the
Dose-Dependent Anti-HIV Effects by IFN- Subtypes
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FIG 2 Dose-dependent HIV-inhibitory activity of IFN- subtypes as examined in primary cells infected ex vivo. (A and B) CD4 T cells,
PBMCs, or MDMs were pretreated with the indicated IFN- subtype for 2 h and then inoculated with HIV YU-2 overnight. The next day,
the cultures were washed and the IFN-s added back. At days 0, 4, 8, and 12, supernatant was harvested to monitor HIV replication by
quantifying p24 Ag. The area under the curve of the p24 Ag over time was calculated and normalized to that of the control (i.e., no IFN-).
(A) Data exploring anti-HIV activities of IFN-1, -2, -6, and -14 in subsets of six donors’ CD4 T cells and three donors’ PBMCs at an
(Continued on next page)
Schlaepfer et al.
January/February 2019 Volume 4 Issue 1 e00637-18 msphere.asm.org 6
 o
n
 August 9, 2019 at UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://m
sphere.asm
.org/
D
ow
nloaded from
 
anti-HIV responses in CD4 T cells treated with IFN- were stratiﬁed in terms of donor,
with certain donors consistently displaying low (e.g., donor 577) or high (e.g., donor
597) responsiveness to IFN- treatment regardless of the subtype (Fig. S4). The ob-
served interdonor variability (50.24%, versus 36.86% attributed to IFN- subtype;
two-way ANOVA) supports the notion that some individuals are more responsive than
others to IFN- treatment (host factors associated with resistance to IFN- treatment
are reviewed in reference 32).
Only modest differences in antiviral activities of human IFN- subtypes at
maximal treatment doses. As we observed a convergence of the anti-HIV activities of
IFN-1, -2, -6, and -14 at high treatment doses, we tested the anti-HIV effects of all
IFN- subtypes at 1,000 pg/ml in CD4 T cells and PBMCs. This allowed us to evaluate
the amount of residual HIV replication in the presence of maximally suppressive IFN-
concentrations compared to the level of viral replication in the untreated control (Vres)
(Fig. 3) (30). For all IFN- subtypes, with the exception of IFN-1, the mean Vres was
below 10% HIV replication. These results mirror the dose-dependent trends in the
IFN-s’ signaling activities (Fig. 2) and point toward similar anti-HIV activities between
IFN- subtypes at high treatment doses. Note, we again observed cell type-speciﬁc
differences in the Vres for the IFN- subtypes.
FIG 2 Legend (Continued)
extended dose range. (B) Data for IFN-1, -2, and -6 in cells from larger numbers of donors (12, 9, and 9 donors, respectively), focusing
on higher dosages of the IFN- subtypes. Responses were compared to those measured in the IFN-2-treated groups by signiﬁcance
testing with RM two-way ANOVAs, comparing all groups to the IFN-2 group. Symbols for comparisons with IFN-2 are as follows: *,
IFN-1; #, IFN-6. (C) Data for fold changes in anti-HIV activities compared to that of IFN-2 for IFN- subtypes and donor cells as described
in the legend to panel B. (D) Percentages of inhibition in donor-matched cell subsets for IFN-1, -2, and -6 at 10 pg/ml. Signiﬁcance
testing was done for each IFN- subtype using RM one-way ANOVAs, comparing the responses in each cell type to one another.
FIG 3 IFN subtypes converge in their anti-HIV activities at 1,000 pg/ml, with the exception of IFN-1.
PBMCs were pretreated with the IFN- subtypes and infected with HIV YU-2 overnight. The next day, the
cultures were washed and IFN-s added back. Vres was assessed for all subtypes (n 3 donors, in
duplicates). Signiﬁcance testing was done using RM one-way ANOVAs, comparing all IFN- treatment
groups to IFN-2.
Dose-Dependent Anti-HIV Effects by IFN- Subtypes
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Preserved afﬁnity of IFN mutants for IFNAR2 is critical for their anti-HIV
activity, but reduced afﬁnity of IFN mutants for IFNAR2 might be compensated by
increased afﬁnity for IFNAR1, resulting in superior anti-HIV activity. Using a panel
of IFN-2 mutants with different afﬁnities for IFNAR1 or -2, we examined the role of
IFNAR1 versus that of IFNAR2 in inhibiting HIV replication in primary CD4 T cells and
PBMCs (Fig. 4). The binding afﬁnities of the IFN-2 mutants are given in relation to the
binding afﬁnity of IFN-2 (set as 1), and an overview of these mutants is provided in
Table 2. The IFN-2 A145G variant (IFN-2-145G; bearing a change of A to G at position
145) (33), which displays an 33-fold reduction in binding to IFNAR2, stood out for its
marked reduction in anti-HIV activity compared to that of IFN-2. Notably, the IFN-2
L26A variant (IFN-2-26A) (34), which binds to IFNAR2 with only 5-fold lower afﬁnity
than IFN-2, exerted anti-HIV activity comparable to that of IFN-2 (P 0.9959). On the
other hand, the YNS variant (bearing the mutations H57Y, E58N, and Q61S) (35), which
has a binding afﬁnity for IFNAR1 60 times stronger than that of IFN-2, displayed
superior anti-HIV activity in CD4 T cells (P 0.0002) and a similar trend in PBMCs
(P 0.0559), pointing to the importance of IFNAR1 for the potency of the anti-HIV
response. The YNS variant with the C-terminal tail of IFN-8 (YNS8T) (36), which
exhibits a 22-fold increased binding afﬁnity for IFNAR2 in addition to a high binding
FIG 4 IFN-2 mutants with modiﬁed IFNAR binding afﬁnities display differential anti-HIV activities compared to
that of IFN-2. (A) Puriﬁed primary CD4 T cells and PBMCs were pretreated with either IFN-2 or the mutants for
2 h and then inoculated with HIV YU-2 overnight. The next day, the cultures were washed and IFN-s added back.
At days 0, 4, 8, and 12, supernatants were harvested for monitoring HIV replication by quantifying p24 Ag. The areas
under the curve of the p24 Ag over time were calculated and normalized to that of matched controls (n 3
donors). Signiﬁcance testing was done using RM two-way ANOVAs, comparing all mutants to IFN-2. Symbols for
comparisons with IFN-2 are as follows: *, YNS; #, YNS-8T; §, YNS-148A; °, IFN-2-145G; %, IFN-2-8T; †,
IFN-2-26A. (B) Vres values for all of the mutants (n 3 donors, in duplicates). Signiﬁcance testing was done using
RM one-way ANOVAs, comparing mutants to IFN-2.
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afﬁnity for IFNAR1, showed anti-HIV activity comparable to that of YNS in CD4 T cells
(paired t test, P 0.3488) and PBMCs (paired t test, P 0.0921), suggesting that the
additional increased binding afﬁnity of this mutant for IFNAR2 did not augment its
antiviral activity. Indeed, the IFN-2 variant with only its C-terminal tail exchanged for
that of IFN-8 (IFN-2-8T) (34) showed antiviral activity comparable to that of IFN-2
in PBMCs (P 0.5982), whereas in CD4 T cells, it surprisingly exerted a higher antiviral
activity (P 0.0015). Moreover, the YNS M148A variant (YNS-148A) (25), which displays
60-fold reduced binding to IFNAR2 and 60-fold increased binding to IFNAR1,
blocked HIV replication similarly to IFN-2 (P 0.7823), suggesting that this mutant
compensated for its reduced binding to IFNAR2 with its markedly higher binding to
IFNAR1. Thus, binding to IFNAR2 appears to be critically needed for an effective anti-HIV
response, but increased binding to IFNAR1 can potentiate antiviral potency or com-
pensate for reduced binding to IFNAR2.
DISCUSSION
Given the prevailing controversy surrounding the functional role of the 12 distinct
human IFN- subtypes that all signal through a common receptor complex, in this
study, we reexamined whether IFN- subtypes induce different biological activities,
with a focus on how the IFN- treatment dose affects HIV replication. Whether and how
IFN- subtypes administered systemically at clinically relevant doses (i.e., supraphysi-
ological doses) (19) may induce differential antiviral or antiproliferative activities is
important to fully harness their therapeutic efﬁcacy. Overall, our results support the
idea that while IFN- subtypes display different potencies in their various cellular
activities, they do not intrinsically induce different biological responses, given that each
subtype is exogenously applied at a high enough dose.
We show that differential levels of induction of ISRE-dependent gene expression by
the 12 IFN- subtypes are dose dependent, with differences only evident at lower
treatment doses and a convergence of the signaling activities of all subtypes at
treatment doses above 100 pg/ml, except for IFN-1, which required doses above
1,000 pg/ml. Based on those data, the IFN subtypes can be categorized as low (IFN-1),
intermediate (IFN-s 2, 4, 5, 7, 8, 10, 16, 17, and 21), or high (IFN-s 6 and 14) inducers
of gene expression at subsaturating doses, a classiﬁcation which largely reﬂects the
subtypes’ IFNAR2 binding afﬁnities (7). This is in line with the concept that although full
activation of the IFNAR occurs with different efﬁciencies for each subtype, once the
receptor is fully activated, IFN signaling is indistinguishable between subtypes (27). The
fact that IFN-1’s binding afﬁnity for IFNAR2 is approximately 2 orders of magnitude
weaker than those of all other subtypes may explain why IFN-1 appeared as an outlier
and necessitated a much higher dose to reach maximal signaling activity. Furthermore,
we demonstrate that disparities in the anti-HIV activities of IFN- subtypes are also dose
dependent (Fig. 2), with reduced antiviral activity compensated for by increasing the
treatment dose. Notably, differences in the IFN- subtypes’ dose-response curves
provide evidence that the subtypes are unequally potent against HIV (IFN-6  IFN-
2  IFN-1), which, as discussed previously, is likely to be a consequence of differ-
TABLE 2 Overview of IFN-2 mutants used in this study
Mutant Description of mutation(s)
Binding afﬁnity fora:
Anti-HIV activity
(P value)b Reference(s)cIFNAR1 IFNAR2
IFN-2-145G A145G 1 33 24.94 (0.0001) 33
IFN-2-26A L26A 1 5 2.364 (0.9789) 34
IFN-2-8T C-terminal tail replaced with that of IFN-8 1 20 16.46 (0.0015) 34
YNS H57Y E58N Q61S 60 1 19.68 (0.0002) 35
YNS-8T YNS  C-terminal tail replaced with that of IFN-8 60 20 15.55 (0.0027) 36
YNS-148A YNS  M148A 60 60 10.5 (0.0608) 1, 24, 25
aBinding afﬁnity compared to that of IFN-2.
bMean difference in Vres results compared to the result for IFN-2 in CD4 T cells (see Fig. 4B). Signiﬁcance testing was done using RM one-way ANOVAs, comparing
all mutants to IFN-2.
cThe references cited in the last column are the papers that assessed the mutants’ binding afﬁnities for IFNAR1 and IFNAR2.
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ences in their afﬁnities for IFNAR. Nevertheless, at maximal treatment concentrations,
all IFN- subtypes except IFN-1 displayed similarly high anti-HIV effects (i.e., Vres of
10%) (Fig. 3), and we suppose that at even higher treatment doses, the maximal level
of HIV inhibition achieved by each subtype would be indistinguishable. Thus, despite
disparities in their potencies, our results suggest that IFN-s intrinsically have compa-
rable anti-HIV activities. These ﬁndings also highlight the importance of considering a
wide range of IFN doses in order to be able to distinguish genuine differences in the
functional activities of IFNs from dose-dependent differences in potencies and signal-
ing efﬁciencies. Furthermore, macrophages were more responsive than CD4 T cells to
IFNs. This might be due to the higher expression level of IFNAR in monocytes/
macrophages than in CD4 T cells (37).
The dose-related effects identiﬁed in this study are not without precedence in the
IFN body of literature (14, 27, 30, 38). For example, Moll et al. reported that the
maximum ISG expression levels were ultimately comparable between IFN- subtypes
even though the subtypes displayed different potencies in terms of the dose required
for half-maximal ISG induction. In their study, differences in IFN- activities were only
detected at subsaturating doses (14). Similarly, Fenton-May et al. showed that although
exogenous IFN-2 was more potent than IFN- in inhibiting HIV replication (i.e., lower
IC50 value), when maximally inhibitory concentrations of each subtype were applied,
the extents of viral inhibition were similar (30). This dose effect may explain discrep-
ancies between our ﬁndings and those of studies that, conversely, claim that IFN-
subtypes mediate differential anti-HIV activities (16, 17, 26, 28). Namely, Harper et al.
reported differential antiviral activities between IFN- subtypes, with IFN-6, -8, and
-14 blocking HIV most efﬁciently in ex vivo-infected human intestinal lamina propria
aggregate cultures (17). In a follow-up study, Lavender et al. conﬁrmed that IFN-14
was more potent in suppressing HIV replication than IFN-2 in a humanized mouse
model (16), and these results were corroborated by Abraham et al., in whose study IFNs
were compared in another humanized mouse model by hydrodynamic injection of
plasmids encoding the IFNs (26). However, critically, in these three studies, only single
treatment doses (i.e., 100 pg/ml or 1.5 105 U/mouse) or unregulated IFN doses (i.e.,
expression from naked plasmid DNA) were investigated. Indeed, if we had only eval-
uated the level of HIV inhibition achieved with 100 pg/ml of IFN- subtypes 1, 2, and
6, we would also have concluded that the subtypes mediated differential antiviral
activities. However, in reality, the anti-HIV activities of these three proteins converged
at higher doses. Therefore, although the aforementioned studies provide a valuable
indication for including IFN-14 in anti-HIV therapies, they do not provide evidence
that IFN- subtypes intrinsically differ in their functional roles.
Furthermore, we show that the ISG proﬁles induced in primary CD4 T cells treated
with a saturating dose (1,000 pg/ml) (Fig. 1A) of IFN-1, -2, -6, and -14 are
qualitatively very similar (i.e., essentially identical sets of genes induced) (Fig. 1B).
Nevertheless, differences in gene expression levels induced by the subtypes tested
were observed (Fig. 1C and Table 1) and mirrored the subtypes’ binding afﬁnities for
IFNAR2, suggesting that binding afﬁnity for IFNAR2 is an important determinant of the
IFN- subtypes’ signaling efﬁciencies and consequently, the level of ISG induction. We
postulate that at higher treatment doses, these quantitative differences between
subtypes would largely disappear, as seen in a study by da Silva et al., where IFN-2 and
IFN- were capable of inducing qualitatively and quantitatively similar ISG proﬁles in
human umbilical vein endothelial cells only when saturating doses of IFN were used
(27). The similarity of the ISG responses produced by IFN-1, -2, -6, and -14
treatment is in accord with the aforementioned principle that the activated receptor
complexes formed with IFNAR by the different IFN- subtypes intrinsically possess the
same signaling properties (albeit with different efﬁciencies) (27) and implies that
sufﬁciently high IFN- concentrations can compensate for the differences in signaling
and gene expression. Contrarily, Cull et al. proposed that differential biological effects
of IFN- subtypes may be explained, at least in part, by their ﬁnding that IFN-
subtypes selectively activate different STAT molecules in J2E cells (38). However, in that
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study, only two IFN doses were tested in their STAT activation assays, limiting the
validity of their claims, and even so, we can appreciate a dampening of differences in
activation of STATs between IFNs at the higher dose.
Furthermore, we found that the cell donor had a greater inﬂuence on the ISG
response proﬁle and anti-HIV activity induced by IFN- treatment than the actual
subtype used for treatment (27). In other words, the genetic traits of the individual were
dominant over more subtle biological differences induced by the different IFN-
subtypes. These results strongly support the notion of interdonor variability in respon-
siveness to IFN- therapy (32) and highlight the importance of assessing whether a
patient is likely to respond well to IFN- therapy by evaluating known host factors
involved in modulation of IFN- responsiveness.
Finally, in an attempt to identify avenues by which IFN therapy could be rendered
more effective, we used a panel of IFN-2 mutants (Table 2) to identify patterns in
binding afﬁnities for IFNAR1 and IFNAR2 associated with differential anti-HIV potencies.
The IFN-2-145G mutant, which was the least potent IFN-2 variant in our HIV
inhibition dose dependency assays, is distinguishable from all other variants by its
markedly reduced binding afﬁnity for IFNAR2. On the other hand, the YNS mutant,
which binds IFNAR1 with much greater afﬁnity than IFN-2, and the YNS-148A mutant,
which in addition has a very low afﬁnity for IFNAR2 compared to that of IFN-2, both
displayed signiﬁcantly greater anti-HIV activities than IFN-2 at maximal concentration.
However, compared to one another, these two YNS mutants exerted comparable
antiviral activities, implying that, provided there is strong IFNAR1 binding, binding to
IFNAR2 is of lesser signiﬁcance. Thus, we identify IFNAR2 binding as essential to IFN-’s
anti-HIV activity, whereas a heightened binding afﬁnity for IFNAR1 enhances antiviral
activity (Fig. 4). Notably, we show that in the case of reduced IFNAR2 binding, anti-HIV
activity can be rescued by increased binding to IFNAR1.
In summary, we provide evidence that all the IFN- subtypes exert potent anti-HIV
activity and trigger a similar ISG response at saturating doses. Our investigations imply
that the biological responses induced by IFN- subtypes are intrinsically equivalent,
with lower functional activities easily compensated for by increasing treatment doses.
We propose that reported differences between IFN- proteins largely arise from the use
of subsaturating treatment doses and that, therefore, dose effects should always be
considered in analyses of IFN- subtypes’ functional activities. With regard to IFN-
therapy, our study identiﬁes the development of mutants with increased binding
afﬁnity for IFNAR1 rather than the use of a speciﬁc IFN- subtype as a promising avenue
to improve treatment outcomes. Finally, it is imperative that interindividual differences
in responsiveness to IFNs are considered in future studies investigating these proteins’
biological activities and potencies (16, 17, 26).
Of note, we identify some limitations to our study. First, we interrogated the
biological activities of IFN- subtypes in simplistic primary cell models. Although
primary cells are more physiologically relevant systems than cell lines, they cannot fully
recapitulate the complexity of the human immune system’s interaction with pathogens.
The differences in response to IFN- treatment between CD4 T cells, PBMCs, and
MDMs highlight this notion. Second, large variations in the responses to IFN- treat-
ment due to variability in donor responsiveness, as well as donor-dependent differ-
ences in HIV replication levels, reduced our ability to statistically validate signiﬁcant
trends in the data. To account for these sources of intergroup variability, we used
repeated measures in our study design and analyses. A prescreening of donor host
factors prior to use of that donor’s samples may be judicious in future studies. Third, we
did not include all 12 IFN- subtypes in all our assays, and thus, we cannot exclude the
possibility that one of the subtypes not extensively tested displays some superior
biological functionalities. Nevertheless, like many other studies, we extensively assessed
the biological activities of representative IFN- subtypes from each class of IFNAR
binding afﬁnities.
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MATERIALS AND METHODS
Cells and reagents. The human retinal pigment epithelial cell line containing an ISRE-driven reporter
gene (ATCC CRL2302) was grown in Dulbecco modiﬁed Eagle medium (DMEM) supplemented with 10%
fetal calf serum (FCS) and 1% penicillin–streptomycin. Peripheral blood mononuclear cells (PBMC) were
isolated from buffy coats using Ficoll gradient centrifugation. CD4 T cells were isolated using Mi-
croBeads (Miltenyi). They were cultured in RPMI medium supplemented with 10% FBS, interleukin-2 (IL-2)
at 10 U/ml, 2 mM L-glutamine, and 1% penicillin–streptomycin. Monocyte-derived macrophages (MDMs)
were generated by culturing monocytes at a concentration of 5 104 cells/well in a 96-well plate in RPMI
1640 medium supplemented with 10% human AB serum, 10 ng/ml macrophage colony-stimulating
factor (M-CSF), 2 mM L-glutamine, and 1% penicillin–streptomycin for 6 days. Thereafter, cells were
cultured for an additional 2 days in medium lacking cytokines.
The IFN- subtypes were from PBL Assay Science (catalog number 11002-1). Furthermore, we
examined a number of IFN- mutants with different afﬁnities, which were generated as previously
described (35, 39).
HIV infection. The CCR5-tropic HIV YU-2 molecular clone was transfected into HEK293T cells using
polyethyleneimine (Polysciences). Supernatants were harvested 48 h later, clariﬁed by ﬁltration (0.22 M),
aliquoted, and stored at 80°C until use. The titers of virus stocks were determined as described in
reference 40. Brieﬂy, 2 105 CD8-depleted PBMCs from three healthy donors were activated with
recombinant IL-2, polyhemagglutinin (PHA), and OKT3 antibody for 2 days and then challenged, in
quadruplicate, with 1:5 serial dilutions of virus stock. After 7 days, supernatants were harvested and p24
antigen (Ag) concentrations were determined by an in-house p24 Ag enzyme-linked immunosorbent
assay (ELISA). The 50% tissue culture infectious dose (TCID50) was then determined based on the number
of p24-positive wells and the Reed and Muench calculation. For the HIV inhibition assays, 2 105 PBMCs
or CD4 T cells were plated in triplicate in round-bottom 96-well plates, pretreated with the IFN-
subtypes for 2 h, and infected overnight with YU-2 at an MOI of 0.01, washed three times with
phosphate-buffered saline (PBS), and then cultured in medium containing the different IFN- subtypes.
Culture supernatants were collected every 3 to 4 days and stored at 20°C until p24 Ag quantiﬁcation
by ELISA. The level of HIV inhibition (% HIV inhibition) was calculated by ﬁrst determining the area under
the curve (AUC) of the p24 Ag concentration over time, followed by expressing the AUC of the
IFN--treated sample as a percentage of the matched mock-treated sample and subtracting this value
from 100.
Pathway-focused gene expression analysis using the interferons and receptors RT2 proﬁler
PCR array. We applied the interferons and receptors RT2 proﬁler PCR array (catalog number PAHS-064Z;
Qiagen) protocol as provided by the manufacturer. Brieﬂy, we stimulated 3 106 PBMCs with IFN-1,
-2, -6, or -14 at 1,000 pg/ml for 6 h. The cells were then harvested and lysed with the RLT lysis buffer.
We then extracted RNA using the RNeasy minikit (catalog number 74106; Qiagen) and performed a
DNase digest on the columns. Subsequently, we reverse transcribed 1 g RNA for subsequent PCR on
Bio-Rad iQ5. The gene expression analyses were done with Qiagen’s GeneGlobe data analysis software.
Gene expression data for each IFN--treated sample are reported as fold changes relative to the results
for matched untreated controls. Therefore, a value of zero signiﬁes no increase in expression compared
with the expression in the control samples. Since most of the genes in this PCR array are upregulated
from slightly to very vigorously and only a few were modestly downregulated, we have chosen distinct
scales for the up- versus downregulated genes. If we had applied the same scale for up- and down-
regulated genes, the downregulated ones would not be discernible.
Statistical analysis. All statistics were performed using the built-in analysis packages from GraphPad
Prism 7.04 (GraphPad Software, Inc., La Jolla, CA). Data were analyzed with either repeated measures
one-way or two-way ANOVA with Dunnett’s multiple-comparison test, unless stated otherwise in the text
or in the ﬁgure legends. We considered a P value of 0.5 signiﬁcant, and signiﬁcance testing is reported
as exact P values in the text or using symbols in the ﬁgures. Results are reported as mean values 	
standard errors of the means (SEM), and ﬁgures depict group means and SEM, unless stated otherwise
in the legend. Levels of signiﬁcance are indicated as follows: single symbols, P 0.05; double symbols,
P 0.01; triple symbols, P 0.001.
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